title: Monoclonal antibodies and idiotypic network activation for ovarian carcinoma.
abstract: Antibodies can be processed by the B- and T-cell systems and may lead to a selective activation of the immune system. The network structure of the immune system implicates the possibility of a selective immunization by the activation of idiotypic cascades. In a retrospective analysis, patients with advanced ovarian carcinoma, who had received MAb, against the cancer-associated antigen CA125 for diagnostic purposes, were analyzed for the production of anti-idiotypic antibodies, survival rate, and immunological effects. Furthermore, we started a prospective and randomized study for ovarian cancer patients, using a different antigen, TAG72, for the induction of idiotypic cascades. Our first results on 58 patients with advanced ovarian carcinomas showed that the induction of anti-idiotypic-antibodies against OC125 mimicking the TAA Class III CA125 leads to a prolongation of the survival rate, and, in extended stages, to an induction of antitumoral immunity, and that the induction of idiotypic cascades is also possible for different antigens like TAG72. Summarizing the activation of idiotypic network cascades seems to be a very effective way of intervention in the immune system of patients with advanced stages of ovarian carcinoma. A prospective study of the adjuvant approach seems to be necessary.
authors.affiliation: Dept. of Gynecology and Obstetrics, University of Bonn, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Wagner
authors.forename: J
authors.initials: J
authors.lastname: Reinsberg
authors.forename: S
authors.initials: S
authors.lastname: Schmidt
authors.forename: P
authors.initials: P
authors.lastname: Mallmann
authors.forename: J
authors.initials: J
authors.lastname: Schmolling
authors.forename: B
authors.initials: B
authors.lastname: Schultes
authors.forename: H
authors.initials: H
authors.lastname: Richter
authors.forename: H J
authors.initials: HJ
authors.lastname: Biersack
authors.forename: D
authors.initials: D
authors.lastname: Krebs
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000276:immunology*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*; D011446:Prospective Studies; D012189:Retrospective Studies
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D018394:CA-125 Antigen